In the setting of ERBB2-amplified metastatic CRC, a favorable response to anti-HER2 therapies has been demonstrated. Trastuzumab deruxtecan, an antibody-drug conjugate, has shown promise in this setting. Currently, there are no approved HER2-targeted therapies for CRC.
Learn more about HER2-targeted therapies for metastatic CRC.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Ali Alqahtani. Fast Five Quiz: Precision Medicine and Genetic Testing for Colorectal Cancer - Medscape - Jun 17, 2022.